DrugPatentWatch Database Preview
Mylan Ireland Ltd Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for MYLAN IRELAND LTD, and when can generic versions of MYLAN IRELAND LTD drugs launch?
MYLAN IRELAND LTD has five approved drugs.
There are thirteen US patents protecting MYLAN IRELAND LTD drugs.
There are sixty-one patent family members on MYLAN IRELAND LTD drugs in thirty-one countries and one supplementary protection certificate in one country.
Summary for Mylan Ireland Ltd
| International Patents: | 61 |
| US Patents: | 13 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 5 |
Drugs and US Patents for Mylan Ireland Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Ireland Ltd | PRETOMANID | pretomanid | TABLET;ORAL | 212862-001 | Aug 14, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | 8,273,894 | Start Trial | Y | Start Trial | |||
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | 10,106,503 | Start Trial | Start Trial | ||||
| Mylan Ireland Ltd | ARIXTRA | fondaparinux sodium | INJECTABLE;SUBCUTANEOUS | 021345-003 | May 28, 2004 | AP | RX | Yes | Yes | Start Trial | Start Trial | ||||
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | 7,585,879 | Start Trial | Y | Y | Start Trial | ||
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | 7,288,657 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mylan Ireland Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan Ireland Ltd | ARIXTRA | fondaparinux sodium | INJECTABLE;SUBCUTANEOUS | 021345-001 | Dec 7, 2001 | 4,818,816 | Start Trial |
| Mylan Ireland Ltd | MIACALCIN | calcitonin salmon | SPRAY, METERED;NASAL | 020313-002 | Aug 17, 1995 | 5,733,569 | Start Trial |
| Mylan Ireland Ltd | MIACALCIN | calcitonin salmon | SPRAY, METERED;NASAL | 020313-002 | Aug 17, 1995 | 5,759,565 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Mylan Ireland Ltd Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Malaysia | 144482 | Start Trial |
| Spain | 2345640 | Start Trial |
| Germany | 602005006757 | Start Trial |
| Canada | 2765621 | Start Trial |
| Taiwan | 200538438 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2005087738 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mylan Ireland Ltd Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0084999 | 2002C/012 | Belgium | Start Trial | PRODUCT NAME: FONDAPARINUX SODIQUE; REGISTRATION NO/DATE: EU/1/02/206/001 20020321 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
